Contract Service Directory

Sentry Biopharma Services





Company Headquarters

4605 Decatur Blvd.
Indianapolis, IN 46241
United States

Company Description

Sentry BioPharma Services protects product SISPQ through pharmaceutical services: cGMP temperature-controll ed storage (including CS III-V), global distribution, labeling, secondary packaging and import/export optimization. Sentry's long history, validated systems and stringent quality standards support this objective throughout the pharmaceutical supply chain. Sentry’s strategic location within the IND Foreign Trade Zone, allows product from OUS to be received directly and held at temperature, pending approval for importation from the FDA, CBP, USDA and DEA. Sentry is VAWD accredited, licensed in all US states and inspected by numerous international authorities including the PMDA and EMA.

Contract Service Directory

    Content From Sentry Biopharma Services

    Related Content

    • Breaking News | CRO News | Promotions & Moves
      Parexel Adds Experts to Regulatory Consulting Group

      Parexel Adds Experts to Regulatory Consulting Group

      Four new hires from U.S. FDA and MHRA will serve as technical vice presidents
      12.10.19

    • Breaking News | Drug Development | Trials & Filings
      SK Bio Gains FDA Approval for XCOPRI

      SK Bio Gains FDA Approval for XCOPRI

      Marks the first time a Korean company has independently brought a compound from discovery to U.S. FDA approval
      11.25.19

    • Cold Chain Management | Logistics | Serialization | Supply Chain

      Review of FDA DSCSA Guidance Documents

      Brian Daleiden of TraceLink reviews the latest requirements from the FDA and DSCSA


    • Supply Chain
      Effect of Personalized Medicine on the Pharma Supply Chain

      Effect of Personalized Medicine on the Pharma Supply Chain

      As the FDA approves personalized drugs, the pharmaceutical supply chain must transform to meet the demand.
      Alexander Amelin, SVP, client success, SoftServe 11.22.19

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19

    • CPhI Worldwide Event Info


    • AAPS Exhibitor List

      ...
      10.29.19





    • Regulatory Affairs
      Quality Metrics Feedback

      Quality Metrics Feedback

      A look at FDA’s Quality Metrics Initiative, a complicated issue for all of pharma stakeholders
      Gil Roth, President, Pharma & Biopharma Outsourcing Association 09.16.19

    • Breaking News | Clinical Trials | Industry News | Inspections | QA/QC
      FDA Extends CRADA with CluePoints

      FDA Extends CRADA with CluePoints

      Aims to further explore a data-driven approach to quality oversight in clinical trials
      09.11.19


    • Breaking News | Drug Development | Trials & Filings
      FDA Approves Boehringer’s Ofev

      FDA Approves Boehringer’s Ofev

      Becomes the first and only therapy to slow the rate of decline in pulmonary function in systemic sclerosis-associated ILD
      09.09.19

    • cGMP Manufacture | Collaborations & Alliances
      NIIMBL, FDA to Advance Innovation in Bio Manufacturing

      NIIMBL, FDA to Advance Innovation in Bio Manufacturing

      CRADA enables FDA and NIIMBL to support investments in regulatory science research, and training needed to foster advanced manufacturing innovations
      08.01.19

    • Trials & Filings
      FDA Accepts RedHill Biopharma’s NDA for Talicia

      FDA Accepts RedHill Biopharma’s NDA for Talicia

      Commercial launch of H. pylori treatment is planned shortly following potential FDA approval
      07.16.19

    • Extractables and Leachables | Laboratory Testing
      The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

      The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

      Andrew Kolbert of Avomeen discusses FDA oversight of E&L testing, complications that arise, and the expertise needed to keep up with changing quality standards
      Kristin Brooks, Contract Pharma 07.11.19

    • Drug Development | Trials & Filings
      FDA Approves J&J

      FDA Approves J&J's DARZALEX in Multiple Myeloma

      Results showed that DARZALEX significantly reduced the risk of disease progression or death by 44 percent
      06.28.19

    • Trials & Filings
      Sierra’s Momelotinib Granted FDA Fast Track Designation

      Sierra’s Momelotinib Granted FDA Fast Track Designation

      Underscores potential for momelotinib to address unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK inhibitor
      06.19.19